🇺🇸

US SEC Filing Intelligence

· daily

US SEC Trading Suspension Halt Orders — March 23, 2026

Across the single filing in the USA Trading Suspensions stream, Volato Group, Inc. (SOAR) faces severe NYSE American delisting risk due to stockholders’ equity falling below $2.0M (losses in two of three recent fiscal years) and $4.0M (losses in three of four recent fiscal years), signaling prolonged financial distress with no provided YoY/QoQ recovery trends. Negative sentiment dominates with 9/10 materiality, highlighting non-compliance under Sections 1003(a)(i) and 1003(a)(ii) of the Company Guide. No immediate trading suspension impacts Class A Common Stock (SOAR) on NYSE American, but warrants (SOARW) already trade on OTC Markets, foreshadowing potential further liquidity erosion. Absent enriched data on insider activity shows no management buying conviction, while forward-looking compliance deadlines (plan by April 16, 2026; regain standards by December 17, 2026) create a high-stakes catalyst calendar. Capital allocation details unavailable, but sustained losses imply strained shareholder returns with no dividends or buybacks noted. Portfolio-level theme: isolated small-cap aviation player exemplifies regulatory vulnerability amid equity deficits, urging immediate position reviews.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 23, 2026

Across 38 US SEC filings dated March 23, 2026, focused on boardroom changes, a dominant theme emerges of strategic leadership successions and transitions, with 12 positive sentiment cases (e.g., orderly CEO handovers in 4 Gladstone entities), 15 neutral director retirements/resignations, and 5 negative/mixed signals amid operational challenges like missed milestones. No broad YoY revenue growth trends reported, but period comparisons highlight BioAtla's 2025 bonus misses (0% payout) vs retention incentives for 2026 milestones, contrasting with reaffirmed FY26 outlooks (Cardinal Health). Insider-like conviction shines in internal promotions (e.g., Oil States CFO to CEO, Crawford interim to permanent) signaling stability, while 7 CEO/CFO departures raise continuity risks. Portfolio-level pattern: Biotech/healthcare (8 filings) shows 50% turnover rate with mixed milestones; finance/REITs (10 filings) emphasize governance separations (Chairman/CEO split). Forward catalysts cluster Q2 2026 (earnings, AGMs, milestones), implying near-term volatility but alpha in smooth transitions. Capital allocation leans retention bonuses/RSUs over buybacks, with no dividend/split changes noted.

38 high priority 38 total filings
· daily

US Merger & Acquisition SEC Filings — March 23, 2026

The 10 filings reveal heightened US M&A and takeover activity dominated by SPACs (7/10 filings), with extensions, approvals, and high redemptions signaling persistent deal momentum amid liquidity pressures; actual sector M&A includes mining consolidation (Coeur-New Gold boosting 2026 gold production guidance 80% YoY from 419k oz to 680-815k oz), reinsurance divestiture (FG Nexus), crowdfunding expansion (StartEngine-Vinovest adding $140-150M AUM), and governance tweaks post-acquisition (Exact Sciences). Period-over-period trends show SPAC trust deposits for extensions (YHN $150k) contrasting low balances (TETE $142k signaling redemptions), while Coeur's reserves integration extends mine life to 2032-2035 with strong FCF projections. Capital allocation shines in Coeur's $750M buyback and inaugural $0.02/share dividend vs prior $400M facility upgrade to $1B revolver. Overarching themes: SPAC resilience via extensions/name changes (Goldenstone to Chi Special) but delisting risks (Bayview); positive sentiment in 6/10 filings drives alpha in mining/alts, mixed in SPACs due to redemptions (Crane 19.4M shares/$201M). Portfolio implication: Favor completed M&A with guidance upside over pre-merger SPACs; monitor March 26-31 catalysts for volatility.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 23, 2026

Across 50 overnight SEC filings, dominant themes include mixed 2025 full-year results in 10-Ks with revenue growth in select miners/banks (e.g., Idaho Strategic +64.6% YoY, Finwise +26% net income) offset by declines in consumer/hospitality (Aterian -30.4%, Ashford -5.8% revenue), alongside M&A progress (Thermon/CECO synergies >$40M, Sealed Air regulatory clearances), debt refinancings (Nortech $15M revolver to 2029, Ormat $750M notes), and biotech catalysts (Apogee 52-week data supporting Phase 3 in 2H2026). Portfolio-level trends show 7/15 10-Ks with revenue growth averaging +28% YoY but 5 with net losses widening (avg +45%), margin compression in 4/10 (avg -200bps), and improving balance sheets in 6/10 via debt reduction/cash builds. Positive capital allocation signals like News Corp $1B buybacks and Ormat stock repurchases contrast cyber risks (Heritage incident) and delisting threats (Volato). Critical developments: Faraday Future SEC clearance removes overhang; Apogee AD data positions for $50B market. Implications favor energy/mining longs, M&A arbitrage, caution hospitality/consumer shorts amid pre-market positioning.

36 high priority 14 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 22, 2026

Tayo Rolls Limited (Stock Code: 504961) exemplifies a high-priority insolvency event with prolonged Corporate Insolvency Resolution Process (CIRP) ongoing since October 30, 2019, now exceeding 6 years without full resolution. NCLT approved JBVNL's acquisition resolution plan on December 17, 2024, but implementation remains stayed by NCLAT, leading to a deadlock in quarterly and annual statutory compliances for periods ended March 31, 2025. The erstwhile Compliance Officer, Harpreet Kaur Bhamra, cites inaction by Resolution Professional M. Anish Agarwal and Successful Resolution Applicant (JBVNL), compounded by inoperative company email and website. Negative sentiment prevails with 9/10 materiality, signaling severe governance and operational paralysis. No period-over-period financial comparisons, ratios, or operational metrics available due to insolvency stasis, highlighting zero growth or margin trends amid stagnation. Portfolio-level implication: single distressed manufacturing asset underscores risks in unresolved bankruptcies, advising avoidance for long-only investors. Critical market event flags potential delisting or further value erosion for shareholders.

1 high priority 1 total filings
· daily

Biotech Small-Cap Approvals — March 21, 2026

Seven ANDA approvals dominated the period, with 6 neutral signals for routine generic entries and 1 bullish for DR REDDYS on ELTROMBOPAG, clustered heavily on 2026-03-16 (5 approvals). Indian generics firms (DR REDDYS x2, GLENMARK PHARMS LTD, CIPLA LTD) led activity, signaling steady pipeline execution but limited upside absent special designations or market details. Investors face muted portfolio impacts from pricing pressures and unspecified indications, prioritizing DR REDDYS for dual approvals.

7 total filings
· daily

New Drug Approvals (Original) — March 21, 2026

FDA approvals from March 16-18 (reported March 21) show 2 bullish original NDAs (22% of total) for GSK and Janssen Biotech, featuring NME status with Orphan and Priority designations, signaling premium pricing and exclusivity potential. The dominant pattern is 7 neutral ANDA generics (78%), concentrated among Indian sponsors (Dr. Reddy's x2, Cipla, Glenmark), enabling portfolio expansion but facing pricing pressures. Unspecified indications across all 9 limit revenue quantification; prioritize NME launches for upside, generics for volume plays.

9 total filings
· daily

HHS & Healthcare Contracts Intelligence — March 21, 2026

Spectral MD secured an $86.6M BARDA contract for burn wound imaging R&D, with $49.6M already outlayed on a 7-year deal potentially reaching $127.8M including options, signaling robust federal support for U.S. medtech innovation. This full-competition award to a small business underscores BARDA's commitment to preparedness tech amid high execution already. Investors gain a bullish entry into niche biotech R&D with monitored long-term risks.

1 total filings
· daily

Federal Construction & Infrastructure Contracts — March 21, 2026

Two federal infrastructure contracts totaling $639M to BCCG JV ($368M) and Jacobs ($270M) underscore sustained U.S. government commitment to border security and water supply projects, delivering 2.5-5+ year revenue backlogs via full/open competition wins. Both bullish signals highlight non-small business strength in NAICS 236/237 construction amid early-stage execution. Investors gain visibility into multi-year cash flows but must monitor fixed-price cost vulnerabilities.

2 total filings
· daily

Federal Professional Services Contracts — March 21, 2026

THE PROVIDENCIA GROUP LLC secured a $270M obligation federal contract (potential $485M with options) for HHS refugee sponsor services, with $216M already outlayed, signaling robust revenue visibility through 2026-2027. This single large award dominates the period's professional services stream, highlighting concentration risk in minority-owned consulting firms. Investors should prioritize monitoring option exercises and funding draws amid labor-hour pricing vulnerabilities.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — March 21, 2026

Two bullish Federal IT contracts totaling $565.9M signal robust demand for computer systems design services (NAICS 541512), with $268.5M already outlayed indicating strong execution and cash flow visibility through 2026. Deloitte dominates with a $468M NIH award, while Buchanan & Edwards secures $97M DOL work as a minority-owned firm, highlighting reliable long-term revenue amid high subaward dependencies. Investors should prioritize primes with federal IT exposure for near-term upside from remaining $297M obligations and potential follow-ons.

2 total filings
· daily

New Federal Contractors — March 21, 2026

Eight new federal contracts totaling $2.17B signal robust Q1 2026 federal spending, led by DHS ($881M across security maintenance and border construction) and HHS/DOI ($1.19B in health IT, refugee services, Medicare admin, and R&D). All bullish awards to established non-small businesses emphasize multi-year backlogs with 30-50% average outlays already realized on mature deals, providing revenue visibility through 2030. Investors should prioritize contractors with unexercised options (~$1.8B potential) amid firm fixed-price and cost-plus structures favoring execution over growth speculation.

8 total filings
· daily

Significant Contract Modifications ($10M+) — March 21, 2026

Eight bullish contract modifications totaling $2.17B in obligations signal robust federal spending momentum, with DHS leading at ~$881M (41%) across security maintenance and border construction, followed by HHS (~$648M, 30%) in IT/health services and DOI (~$540M, 25%) in refugee/construction support. Significant outlays averaging 58% of obligations ($1.26B total) across contracts indicate strong execution, while unexercised options add ~$2.3B potential value through 2030. Institutional investors should prioritize DHS/healthcare-exposed firms for backlog growth amid multi-year visibility.

8 total filings
· daily

Contract Deobligations Alert — March 21, 2026

Eight bullish contract signals totaling $2.17B in obligations highlight sustained federal demand in homeland security (DHS: $881M), health services/IT (HHS: $648M), and infrastructure (DOI: $540M), with average 50%+ outlay realization indicating strong execution. Multi-year deals to 2030+ offer backlog visibility, with unexercised options potentially adding $2B+ across winners. Investors should prioritize DHS and HHS exposure for reliable revenue amid full/open competition wins by non-small businesses.

8 total filings
· daily

Contract Option Exercises — March 21, 2026

Eight bullish contract exercises totaling $2.17B signal robust federal spending on homeland security infrastructure ($881M across DHS awards to Techflow and BCCG JV), health IT/services ($647M direct HHS + $270M DOI proxy for HHS ORR), and water construction ($270M DOI to Jacobs). Average 58% outlayed ($1.26B total) on multi-year deals to 2026-2030 indicates strong execution and backlog visibility amid full/open competition wins. Unexercised options exceed $2B potential, prioritizing contractors like Techflow ($1.65B upside) for revenue expansion.

8 total filings
· daily

All HHS Contracts — March 21, 2026

HHS issued three bullish contracts totaling $648M on a single day, dominated by Deloitte's $468M NIH IT upgrade (72% of value), signaling robust federal health IT spending alongside Medicare admin and medtech R&D. Combined outlays of $284M (44% of obligations) confirm execution momentum with revenue visibility to 2030. Investors gain actionable exposure to stable gov cash flows, but prioritize monitoring ~$140M unexercised options across awards.

3 total filings